1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Sunbelt Rentals Holdings completed the sale of $450 million of 4.950% senior notes due 2030 and $750 million of 5.650% senior notes due 2036 on July 14, 2026. The notes add $1.2 billion of long-term debt, with interest payable semi-annually starting February 12, 2027, and rank equal with the company's existing and future senior debt.
2030 Notes: $450 million at 4.950%, issued at 99.627%, maturing August 12, 2030
2036 Notes: $750 million at 5.650%, issued at 99.048%, maturing August 12, 2036
Holders may require repurchase at 101% of principal plus accrued interest upon a change in control triggering event
Notes are jointly and severally guaranteed by domestic subsidiaries that guarantee the revolving credit facility; BNY Mellon serves as trustee
Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America, N.A., extending the senior revolving line of credit to a $50.0 million facility maturing July 10, 2031. The company may request up to an additional $50.0 million in commitments, for a maximum of $100.0 million, subject to lender approval. The filing does not report any borrowings under the facility, and the amendment adds lender liens on substantially all assets and financial covenants that shareholders should note.
Senior revolving line of credit of $50.0 million, maturing July 10, 2031, with an option for up to $100.0 million aggregate commitments
Interest at SOFR plus 0.25% to 1.25%, based on the consolidated leverage ratio; commitment fee of 0.20% to 0.30% per annum on unused amounts
Lenders have a first priority lien on substantially all assets, except certain intangible assets; covenants cover leverage and interest coverage ratios
Amendment dated July 10, 2026; 8-K filed July 14, 2026 with Exhibit 10.1 attached
Research Alliance Corporation IV, a blank check company focused on healthcare, closed its initial public offering on July 14, 2026, selling 7,500,000 Class A ordinary shares at $10.00 each for $75 million in gross proceeds. The IPO and a $2.75 million private placement to the sponsor funded a trust account of $75 million for public shareholders. The filing says the company must complete an initial business combination within 24 months of the IPO closing, or liquidate.
Closed IPO of 7,500,000 Class A ordinary shares at $10.00 per share on July 14, 2026, for gross proceeds of $75,000,000 before underwriting discounts and offering expenses.
Sponsor Research Alliance Holdings IV LLC bought 275,000 private placement shares at $10.00 each, for total proceeds of $2,750,000.
$75,000,000 of net proceeds and private placement funds, including a $2,250,000 underwriter deferred commission, were deposited in a trust account with Continental Stock Transfer & Trust Company as trustee.
Alan Musso and John Maslowski were appointed to the board on July 10, 2026, and each received 30,000 Class B ordinary shares from the sponsor as compensation.
AutoZone completed the sale of $850 million in aggregate principal of 4.950% senior notes maturing July 15, 2031, on July 14, 2026. The notes are senior unsecured debt, so the company takes on new borrowing that must be repaid with interest.
Principal amount of $850 million; fixed interest rate of 4.950% per year, paid semi-annually on January 15 and July 15, starting January 15, 2027
Notes mature July 15, 2031 and rank equally with the company's other senior unsecured liabilities
Issued under an August 8, 2003 indenture with Regions Bank as successor trustee, and sold under a shelf registration filed July 7, 2026
Company may redeem the notes early, and holders may require repurchase after a change of control triggering event
Alto Neuroscience entered into an underwriting agreement on July 13, 2026, to sell 3,776,436 shares of common stock at $26.48 per share in a registered direct offering, with estimated net proceeds of approximately $93.9 million. The company plans to use the proceeds with its existing cash to accelerate ALTO-207 development, including an additional planned Phase 3 trial in treatment-resistant depression. The sale adds new shares outstanding, which dilutes existing holders, and closing is expected July 14, 2026.
Shares offered: 3,776,436 common shares at $26.48 each
Estimated net proceeds: approximately $93.9 million, after underwriting discounts and offering expenses
Use of proceeds: ALTO-207 clinical development, including an additional Phase 3 trial in treatment-resistant depression, and general working capital
Expected closing: July 14, 2026, subject to customary conditions; BofA Securities is representative
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.